ASCO Highlights Seven of 4,000 Abstracts Submitted for Annual Meeting, June 3-7
Analyzing Tumor Tissue In Clinical Trials Can Improve Outcomes, RTOG Trial Finds
Targeting One Specific Protein Can Double PFS; Triple Overall Survival
Revlimid Maintenance Therapy Delayed Progression by 90%
Drug Effectiveness Weakens After Three Years, Study Says
Nexavar Improves PFS In HER-2 Negative Breast Cancer
Xgeva Significantly Increases Bone Metastasis-Free Survival
U.S. Patients Use More Chemotherapy, Less Emergency Care than Canadians
Urocidin May Provide Alternative To Cystectomy in BCG Cancers
Clinical Trials Approved By NCI CTEP Last Month
Afinitor and Sutent Approved For Pancreatic Neuroendocrine Tumors
Abbott PCR Test For HCV Load Sensitive to Within 12 IU/mL
Trending Stories
- Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members
- Long-awaited results from first phase III trial of a RAS inhibitor in pancreatic cancer shows that daraxonrasib doubles median OS
PanCAN’s Berkenblit: “It’s here. This is a tipping point, and we’ve tipped. And this is just the beginning.” - Protecting the cure: Why the future of radiation oncology must be precision-guided
- Letai: Perceptions aside, money is flowing and the cancer research infrastructure is sturdy
NCI expects record-breaking spending on extramural research - NCI Director Letai wants you to know: Grant money is flowing again post-government shutdown
- Wafik El-Deiry steps down as director of Brown’s Legorreta Cancer Center
